Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 40/100

Failure Rate

14.3%

1 terminated/withdrawn out of 7 trials

Success Rate

85.7%

-0.8% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

83%

5 of 6 completed trials have results

Key Signals

5 with results

Enrollment Performance

Analytics

Phase 2
5(71.4%)
Phase 1
2(28.6%)
7Total
Phase 2(5)
Phase 1(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials
NCT05166109Phase 2Completed

A Study to Assess Vamorolone in Becker Muscular Dystrophy (BMD)

Role: lead

NCT03439670Phase 2Completed

A Study to Assess the Efficacy and Safety of Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)

Role: lead

NCT03038399Phase 2Completed

Long-term Extension Study to Assess Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)

Role: lead

NCT04348890Phase 1Withdrawn

Proof of Concept Trial of Vamorolone in Pediatric Ulcerative Colitis

Role: lead

NCT02760277Phase 2Completed

An Extension Study to Assess Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)

Role: lead

NCT02760264Phase 2Completed

A Study to Assess Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)

Role: lead

NCT02415439Phase 1Completed

A Phase 1 Single Ascending Dose and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of VBP15 in Healthy Adult Subjects

Role: lead

All 7 trials loaded